Gliomas are aggressive brain tumors with poor prognosis, and new therapeutic strategies are urgently needed. This study used a combined in silico (computer modeling) and in vitro (laboratory cell) approach to evaluate whether compounds from Cannabis sativa—including cannabichromene (CBC) and cannabigerol (CBG)—as well as related natural molecules, may inhibit the growth of malignant glioma cells. […]
Tag: CBG
Phytocannabinoids and Brain Health: Early Evidence in Parkinson’s and Alzheimer’s Models (pub. June 2025)
Neurodegenerative diseases such as Parkinson’s and Alzheimer’s involve the progressive loss of nerve cells, leading to movement problems, memory decline, and cognitive challenges. Because current treatments often only ease symptoms, researchers are exploring whether phytocannabinoids—naturally occurring compounds from the Cannabis sativa plant—might influence the biological processes behind these disorders. This review article summarizes recent preclinical […]
Cannabigerol (CBG) and Heart Health: What Early Research Suggests (pub. March 2025)
Cardiovascular disease remains a leading cause of illness worldwide, and researchers are exploring new ways to support heart and blood vessel function. This mini‑review article looks at the therapeutic potential of cannabigerol (CBG)—a non‑psychoactive cannabinoid from the cannabis plant—with a particular focus on its possible effects on the cardiovascular system. The authors summarize laboratory and […]